MapLight Therapeutics

Nasdaq: MPLT · SEC EDGAR filings

Results on file1
Average 24h move−73.66%across 1 result with a complete 24h price
1 resultMapLight Therapeutics
Met endpoint

ML-007C

Phase 2 Schizophrenia

MapLight Therapeutics MPLT

24h stock move −73.66%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.